Breast cancer diagnostics market is foreseen to record a modest growth, with more than 25% increase in revenues between 2017 and 2022, according to a Fact.MR report. Various factors have significant impact on growth of the breast cancer diagnostics market, including rising emphasis of pharmaceutical companies on breast cancer-related R&D, and steady improvements in early breast cancer diagnostics and treatment.
In diagnostic platforms of breast cancer, a number of technological advancements have led towards a robust transformation of the global market for breast cancer diagnostics. The emergence of hybrid diagnostics instruments with the provision of an enhanced accuracy have been witnessed in the market.
Advancements such as these have been fuelling growth of the global market for breast cancer diagnostics. Surging cases of breast cancer, coupled with growing older women population are anticipated to create potential growth opportunities for breast cancer diagnostics market across the globe.
The most common type of cancer for women across the globe currently is breast cancer. The number of breast cancer cases is expected to witness a rise, leading towards the requirement for efficient and early breast cancer detection. An established method, mammography, adopted in many countries, has recently been observed to provide inconclusive test results. Personalized and risk-adapted therapy are expected to resolve these difficulties.
You can Get Free Sample Report Here @ https://www.factmr.com/connectus/sample?flag=S&rep_id=55
Estimations for the Global Breast Cancer Diagnostics Market
- BRCA will remain preferred test for breast cancer diagnostics, while revenues from CA test for breast cancer diagnostics are envisaged to register the highest CAGR through 2022, followed by ER & PR. Revenue from ER & PR, and CA tests will continue to be low throughout the forecast period.
- HER 2 test is expected to remain the second largest segment among test type, in the market. However, EGFR mutation test is estimated to account for low revenues in the global market for breast cancer diagnostics.
- North America will continue to be the largest market for breast cancer diagnostics. Revenues from breast cancer diagnostics market in North America is estimated to surpass US$ 800 Mn by 2022-end.
- Europe will remain the second most lucrative region for the breast cancer diagnostics market. However, markets in Japan, and Middle East & Africa (MEA) are anticipated to witness a sluggish expansion throughout the forecast period.
- Hospital-associated labs will remain sought-after among end-users for breast cancer diagnostics around the world. Revenues from breast cancer diagnostics will remain largest in hospital-associated labs, followed by the independent diagnostic laboratories.
- Cancer research institutes are anticipated to exhibit the highest CAGR during the forecast period. Between 2017 and 2022, cancer research institutes are estimated to create absolute $ opportunity of US$ 107.3 Mn.
- Key market players mentioned in Fact.MR’s report include Siemens AG, Myriad Genetics, Inc., Roche Holding AG, Illumina, Inc., Epigenomics AG, Abbott Laboratories, Thermo Fischer Scientific, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., AstraZeneca plc, and Quest Diagnostics Incorporated.
Report Analysis@ https://www.factmr.com/report/55/breast-cancer-diagnostics-market
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Follow us in Linkedin: https://www.linkedin.com/company/factmr/
